Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 173

Similar articles for PubMed (Select 23549429)

1.

Discovery of Rho-kinase inhibitors by docking-based virtual screening.

Shen M, Yu H, Li Y, Li P, Pan P, Zhou S, Zhang L, Li S, Lee SM, Hou T.

Mol Biosyst. 2013 Jun;9(6):1511-21. doi: 10.1039/c3mb00016h. Epub 2013 Apr 3.

PMID:
23549429
2.

Discovery and optimization of triazine derivatives as ROCK1 inhibitors: molecular docking, molecular dynamics simulations and free energy calculations.

Shen M, Zhou S, Li Y, Pan P, Zhang L, Hou T.

Mol Biosyst. 2013 Mar;9(3):361-74. doi: 10.1039/c2mb25408e. Epub 2013 Jan 23.

PMID:
23340525
3.

RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer.

Patel RA, Forinash KD, Pireddu R, Sun Y, Sun N, Martin MP, Schönbrunn E, Lawrence NJ, Sebti SM.

Cancer Res. 2012 Oct 1;72(19):5025-34. doi: 10.1158/0008-5472.CAN-12-0954. Epub 2012 Jul 30.

4.

Development and evaluation of an integrated virtual screening strategy by combining molecular docking and pharmacophore searching based on multiple protein structures.

Tian S, Sun H, Li Y, Pan P, Li D, Hou T.

J Chem Inf Model. 2013 Oct 28;53(10):2743-56. doi: 10.1021/ci400382r. Epub 2013 Sep 24.

PMID:
24010823
5.

Identification of novel ROCK inhibitors with anti-migratory and anti-invasive activities.

Patel RA, Liu Y, Wang B, Li R, Sebti SM.

Oncogene. 2014 Jan 30;33(5):550-5. doi: 10.1038/onc.2012.634. Epub 2013 Feb 11.

6.

Atorvastatin inhibited Rho-associated kinase 1 (ROCK1) and focal adhesion kinase (FAK) mediated adhesion and differentiation of CD133+CD44+ prostate cancer stem cells.

Rentala S, Chintala R, Guda M, Chintala M, Komarraju AL, Mangamoori LN.

Biochem Biophys Res Commun. 2013 Nov 22;441(3):586-92. doi: 10.1016/j.bbrc.2013.10.112. Epub 2013 Oct 29.

PMID:
24177008
7.

A novel anti-tumor inhibitor identified by virtual screen with PLK1 structure and zebrafish assay.

Lu J, Xin S, Meng H, Veldman M, Schoenfeld D, Che C, Yan R, Zhong H, Li S, Lin S.

PLoS One. 2013 Apr 26;8(4):e53317. doi: 10.1371/journal.pone.0053317. Print 2013.

8.

Identification of novel kinase inhibitors by targeting a kinase-related apoptotic protein-protein interaction network in HeLa cells.

Shi Z, An N, Lu BM, Zhou N, Yang SL, Zhang B, Li CY, Wang ZJ, Wang F, Wu CF, Bao JK.

Cell Prolif. 2014 Jun;47(3):219-30. doi: 10.1111/cpr.12098. Epub 2014 Mar 19.

PMID:
24645986
9.

Comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor of Rho kinase or atorvastatin.

Boerma M, Fu Q, Wang J, Loose DS, Bartolozzi A, Ellis JL, McGonigle S, Paradise E, Sweetnam P, Fink LM, Vozenin-Brotons MC, Hauer-Jensen M.

Blood Coagul Fibrinolysis. 2008 Oct;19(7):709-18. doi: 10.1097/MBC.0b013e32830b2891.

10.

Computational approach to the identification of novel Aurora-A inhibitors.

Morshed MN, Cho YS, Seo SH, Han KC, Yang EG, Pae AN.

Bioorg Med Chem. 2011 Jan 15;19(2):907-16. doi: 10.1016/j.bmc.2010.11.064. Epub 2010 Dec 4.

PMID:
21194953
11.

Design of novel rho kinase inhibitors using energy based pharmacophore modeling, shape-based screening, in silico virtual screening, and biological evaluation.

Mishra RK, Alokam R, Singhal SM, Srivathsav G, Sriram D, Kaushik-Basu N, Manvar D, Yogeeswari P.

J Chem Inf Model. 2014 Oct 27;54(10):2876-86. doi: 10.1021/ci5004703. Epub 2014 Oct 9.

PMID:
25254429
12.

Ethyl 2-(benzylidene)-7-methyl-3-oxo-2,3-dihydro-5H-thiazolo[3,2-a]pyrimidine-6-carboxylate analogues as a new scaffold for protein kinase casein kinase 2 inhibitor.

Jin CH, Jun KY, Lee E, Kim S, Kwon Y, Kim K, Na Y.

Bioorg Med Chem. 2014 Sep 1;22(17):4553-65. doi: 10.1016/j.bmc.2014.07.037. Epub 2014 Jul 30.

PMID:
25131958
13.

Molecular modeling studies of Rho kinase inhibitors using molecular docking and 3D-QSAR analysis.

Qin J, Lei B, Xi L, Liu H, Yao X.

Eur J Med Chem. 2010 Jul;45(7):2768-76. doi: 10.1016/j.ejmech.2010.02.059. Epub 2010 Mar 4.

PMID:
20347188
14.

Identification of novel anaplastic lymphoma kinase (ALK) inhibitors using a common feature pharmacophore model derived from known ligands crystallized with ALK.

Xie HZ, Lan H, Pan YL, Zou J, Wang ZR, Li LL, Huang Q, Zhang H, Yang SY.

Chem Biol Drug Des. 2013 Feb;81(2):175-84. doi: 10.1111/cbdd.12084. Epub 2012 Nov 27.

PMID:
23107363
15.

Virtual screening and synthesis of new chemical scaffolds as VEGFR-2 kinase inhibitors.

Elsayed MS, El-Araby ME, Serya RT, Abouzid KA.

Arzneimittelforschung. 2012 Dec;62(12):554-60. doi: 10.1055/s-0032-1323759. Epub 2012 Sep 21.

PMID:
23023518
16.

Synthesis, biological evaluation, and molecular docking studies of novel 2-styryl-5-nitroimidazole derivatives containing 1,4-benzodioxan moiety as FAK inhibitors with anticancer activity.

Duan YT, Yao YF, Huang W, Makawana JA, Teraiya SB, Thumar NJ, Tang DJ, Tao XX, Wang ZC, Jiang AQ, Zhu HL.

Bioorg Med Chem. 2014 Jun 1;22(11):2947-54. doi: 10.1016/j.bmc.2014.04.005. Epub 2014 Apr 13.

PMID:
24792811
17.

Discovery of novel scaffolds for Rho kinase 2 inhibitor through TRFRET-based high throughput screening assay.

Oh KS, Mun J, Cho JE, Lee S, Yi KY, Lim CJ, Lee JS, Park WJ, Lee BH.

Comb Chem High Throughput Screen. 2013 Jan;16(1):37-46.

PMID:
22934984
18.

Identification of CK2 inhibitors with new scaffolds by a hybrid virtual screening approach based on Bayesian model; pharmacophore hypothesis and molecular docking.

Di-wu L, Li LL, Wang WJ, Xie HZ, Yang J, Zhang CH, Huang Q, Zhong L, Feng S, Yang SY.

J Mol Graph Model. 2012 Jun;36:42-7. doi: 10.1016/j.jmgm.2012.03.004. Epub 2012 Mar 26.

PMID:
22516037
19.

Identification of novel polo-like kinase 1 inhibitors by a hybrid virtual screening.

Lu S, Sun SL, Liu HC, Chen YD, Yuan HL, Gao YP, Yang P, Lu T.

Chem Biol Drug Des. 2012 Aug;80(2):328-39. doi: 10.1111/j.1747-0285.2012.01412.x. Epub 2012 Jun 8.

PMID:
22583481
20.

The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models.

Ying H, Biroc SL, Li WW, Alicke B, Xuan JA, Pagila R, Ohashi Y, Okada T, Kamata Y, Dinter H.

Mol Cancer Ther. 2006 Sep;5(9):2158-64.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk